Monroe Biomedical Research

Running trials

• Not yet recruiting

  A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Phase 2· Source

• Recruiting

  A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Phase 3· Source

• Recruiting

  A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

  NCT07845500· Phase 3· Source

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

  NCT07772921· Phase 3· Source

• Recruiting

  A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

  NCT07610278· Phase 2· Source

• Recruiting

  A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

  NCT07570758· Phase 2· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

  NCT07602582· Phase 3· Source

• Recruiting

  A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608· Phase 2· Source

• Active, not recruiting

  A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Phase 2· Source

• Recruiting

  An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

  NCT07543120· Phase 2· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  NCT07321886· Phase 3· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

  NCT07225686· Phase 3· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

  NCT07226765· Phase 3· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Active, not recruiting

  A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

  NCT06857955· Phase 2· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Source

• Recruiting

  To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

  NCT06343298· Phase 2· Source

• Active, not recruiting

  A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

  NCT06662383· Phase 3· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Source

• Active, not recruiting

  A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

  NCT06637371· Phase 1· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Source

• Recruiting

  A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  NCT06143956· Phase 2· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity8 recruiting
• High blood pressure3 recruiting
• Type 2 diabetes3 recruiting
• Alzheimer disease1 recruiting
• Asthma1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

  NCT07030868· Phase 2· Source

• Completed

  "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

  NCT06564818· Phase 3· Source

• Completed

  A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06683508· Phase 2· Source

• Completed

  Wave Crossover ECP Study for Simplified Therapy

  NCT06571370· Source

• Completed

  A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06603571· Phase 2· Source

• Completed

  A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06230523· Phase 2· Source

• Completed

  A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

  NCT05971940· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

  NCT05929079· Phase 3· Source

• Completed

  Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

  NCT05763875· Phase 3· Source

• Completed

  A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05550532· Phase 3· Source

• Completed

  Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

  NCT05616013· Phase 2· Source

• Completed

  A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

  NCT05505734· Phase 3· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

  NCT05362058· Phase 3· Source